cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
japr.editor@gmail.com
Editorial Address
Plot No. 105/42, Opposite electricity sub station, Changorabhata, Raipur (Chhattisgarh), India 492001
Location
,
INDONESIA
Journal of Applied Pharmaceutical Research
Published by Creative Pharma Assent
ISSN : -     EISSN : 23480335     DOI : 10.18231
Core Subject : Health,
Medicine & Pharmacology
Journal of Applied Pharmaceutical Research (JOAPR) is an official publication of Creative Pharma Assent (CPA). It is an open access, peer review online international journal. JOAPR is primarily focused on multiple discipline of pharmaceutical sciences (Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics, Cosmetic Technology, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Herbal drugs/ formulations, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest) which publish quarterly. JOAPR also includes evaluation of pharmaceutical excipients & their practical application to research & industry based efforts. The aim of the scientific journal, JOAPR is to present a wide area for the current researchers to share their noble works and ideas in terms of the research papers, review articles and short communications. JOAPR only publish the original research works with a definite innovation and novelty after thorough reviewing. The paper must have a suitable and proper scientific background.
Arjuna Subject : -
Articles 11 Documents
 1   2 
Search results for , issue "Vol. 12 No. 5 (2024)" : 11 Documents clear
Comprehensive review of breast cancer risk factors, diagnosis, screening, and treatment methods Hoque, Nurjamal; Choudhury, Ananta; Baishya, Dhiraj; Deka, Himangshu
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.606

Abstract

Background: Breast cancer is one of the leading causes of cancer-related deaths among women, accounting for 11.7% of all cancer cases and approximately 685,000 deaths worldwide in 2020. Its multifactorial etiology includes genetic, hormonal, and lifestyle-related risk factors with significant implications for diagnosis and treatment. Understanding these factors and the latest advancements in screening and therapeutic approaches is essential for improving patient outcomes. Methodology: This review synthesizes findings from peer-reviewed articles, clinical trials, and meta-analyses. The focus is on identifying key risk factors for breast cancer, evaluating the effectiveness of current diagnostic methods, and examining the latest treatment strategies, including personalized medicine. Data were collected from PubMed, Scopus, and Google Scholar databases. Results and Discussion: The review highlights major risk factors, including BRCA1/BRCA2 mutations, which contribute to a 45-65% lifetime risk, as well as hormonal influences and lifestyle factors like obesity and alcohol consumption. Targeted therapies, such as HER2 inhibitors (e.g., trastuzumab) and hormone therapies (e.g., tamoxifen), have significantly improved survival rates. Emerging treatments like immunotherapy and PARP inhibitors are also promising for aggressive and metastatic cases. Conclusion: Breast cancer continues to pose a significant health challenge, but advancements in risk assessment, early detection, and personalized treatment offer hope for better outcomes. Continued research and refining diagnostic and therapeutic approaches are essential for reducing breast cancer mortality and enhancing patient quality of life.  
Development and in vitro evaluation of acelofenac mouth dissolving films for reduced analgesic activity Chandra Sekhar Naik D; Bharathi Arigela; Venkata Suresh Babu Agala; Cherukuri Vidyulatha Chowdary
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.612

Abstract

Background: The design of the current research work was to formulate mouth-dissolving films (MDFs) of aceclofenac (ACF) to improve patient compliance and convenience for older and younger patients, ultimately leading to improved therapeutic outcomes. Method: Evaluations were conducted on film formers such as HPMC and MC and film modifiers such as PEG and starch acting as solubilizing agents. Results: The physicomechanical qualities, in vitro disintegration time, and in vitro dissolving characteristics of the produced MDFs were assessed. Good mechanical qualities, including as tensile strength, folding durability, and percentage elongation, were demonstrated by every created MDF. FTIR, SEM, and X-RD analyses were used to assess MDFs. In contrast to other formulations, MDFs containing F8 provided superior dissolving properties. Conclusion: When pitted against other mixtures, the MDFs with sodium alginate (5%), methylcellulose (5%), and hydroxypropyl methylcellulose (HPMC)(5%) showed superior dissolving capabilities. In contrast to other mixtures, the F8 mixture, including HPMC, sodium alginate, and methylcellulose, demonstrated a complete and accelerated dissolution within 50 seconds. The mechanism behind this release is diffusion, as indicated by the release kinetics data.
Exploring the neuroprotective role of probiotics in the therapeutic interventions of cognitive decline J Renukadevi; R Velmurugan; G Nandhinidevi; V S Karthikha; V Sri Vaishnavi
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.648

Abstract

Background: Cognitive decline is developing as a critical alarm in public health concerns initiated by neuroinflammation, an indispensable contributing factor in neurodegenerative diseases. Probiotics and postbiotics have evolved as key therapeutic factors in treating neuroinflammation by modulating neuroinflammatory pathways and therapeutically controlling cognitive decline by its influence on the gut-brain axis. Methodology: This comprehensive review integrates the current status of the insight into the molecular mechanisms of probiotics that promote cognitive health. The review explains their synergistic effects on gut microbiota and their influence on neuroinflammation, mitochondrial function, neurotransmitter levels, and insulin sensitivity. It also explores preclinical and clinical studies involving the neuroprotective benefits of specific probiotic strains. Results: Probiotics are reported to alter gut microbiota by supporting neuroinflammation, thus enhancing cognitive function. The key findings were their role in reducing plaque formation and controlling tau protein hyperphosphorylation, thus improving mitochondrial efficiency. Recent research reveals that strains such as Lactobacillus and Bifidobacterium have proven efficacy in reducing tau phosphorylation and amyloid β pathology in animal models. In addition, probiotics improve insulin sensitivity and neurotransmitter levels, leading to improved cognitive outcomes. Discussion: The microbiota-gut-brain axis is essential in studying the neuroprotective role of probiotics. Probiotics have been reported for their ability to reduce neuroinflammatory markers, leading to improved neurogenesis in the brain's hippocampus. Thus transforming these research findings to clinical therapies requires further research to support and to overcome the limitations and exploring the complete mechanism involved. Conclusion: Probiotics thus being explored to develop as new therapeutic interventions in cognitive decline, with substantial preclinical evidence supporting their benefits. Still persistent research is essential to transform these findings in clinical  trials in the development of  probiotic-based therapies for cognitive health.
In vitro antibacterial and synergistic activity of pyrazolyl sulphonamide derivatives against Staphylococcus haemolyticus Yahaya, Ewura Seidu; Anak, Jesse Azebiik; Amissah, Nana Ama; Obuah, Collins; Agyei, Phyllis Elsie Owusu; Saahene, Roland Osei; Ainooson, Michael; Ablordey, Anthony; Ekor, Martins
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.658

Abstract

Background: Antimicrobial resistance has rendered several   anti-infective agents ineffective, necessitating the need to intensify efforts to identify and develop novel drugs against microbial infection. Structural modification of existing antibiotics continues to be one of the areas of intense research focus in recent times. Objective: This study assessed the antibacterial and synergistic activity of fifteen pyrazolyl sulphonamide derivatives in Staphylococcus haemolyticus. Methods: Antibacterial activity was determined using the broth microdilution method. The ability of test compounds to interact with tetracycline was assessed using the checkerboard synergy testing method and the Loewe synergy and antagonism model. Results: Seven compounds (46.6%) were significantly active against the bacteria (MIC 1 µg/mL – 16 µg/mL), and four were confirmed to form synergistic combinations with tetracycline in checkerboard and Loewe analysis. Conclusion: Observations from this study has demonstrated the antibacterial activity and the synergistic potential of the novel pyrazolyl sulphonamides with tetracycline, highlighting the possible role of modified sulphonamides as a rich resource for antimicrobial development.
Molecular dynamic simulation studies of hemidesmus indicus-derived oleanen-3-yl acetate in stat3 based tumor signaling J Renukadevi; V S Karthikha; J Sam Helinto; D. Prena; Arockiya Rabin A
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.670

Abstract

Background: This study shows how oleanen-3-yl acetate, a plant substance found in Hemidesmus indicus, can be used as a medicine by looking at how it interacts with important signaling proteins in tumor inflammation. Methodology: Molecular docking and dynamics simulation analysis was carried out using PyRx and GROMACS to investigate the binding affinities and the interactions of oleanen-3-yl acetate with critical signaling protein receptors, including STAT3, NF-κB p105, and p53. Results: According to the docking studies, it has a strong binding energy of -8.1 kcal/mol for interacting with STAT3. This supports a strong downregulation of the STAT3-NF-κB signaling axis, a key factor in tumor inflammation. It sheds light on the conformational changes induced by Oleanen derivatives during binding, demonstrating its ability to destabilize the complex and enhance p53's apoptotic activity. Discussion: The RMSD values are maintained below at 2 Å throughout the simulation period, confirming the high structural stability of the ligand-protein complexes, while RMSF analysis is maintained at minimal fluctuation (<1.5 Å) involving key residues,  supporting the best ligand-protein interactions. The fluctuations in root mean square fluctuation (RMSF) and root mean square deviation (RMSD) values further elucidate their involvement in the initiation of apoptosis in cancer cells. Conclusion: It shows an effective way to find new drugs and gives useful information for the future development of therapeutic agents based on Hemidesmus indicus in tumor inflammation.  This research provides a robust technical foundation for further experimental validation and optimization in the drug development pipeline.
Formulation and development of Commiphora myrrha based polyherbal nanoemulsion mouthwash and assessment of its anti-oxidant and cytotoxicity activity Yusof, Norafiqah; David, Sheba R; Mumin, Nuramalina H; Ahmad, Liyana; Rajabalaya, Rajan
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.679

Abstract

Background: A Commiphora myrrha (CM)-based polyherbal mouthwash with enhanced stability and oral bioavailability was developed using a high-energy homogenization method. Methodology: The formulations primarily consist of herbal extracts from CM, ginger, and white tea, optimized based on various parameters, including organoleptic properties, pH, Dynamic Light Scattering (DLS), and Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR- FTIR). Stability studies were also conducted on each formulation. Results and Discussion: The particle sizes ranged from 77 to 216 nm, with zeta potential values between -0.92 and -2.09 ± 0.38 mV, indicating stability. ATR- FTIR studies confirmed no interaction between the ingredients. Antioxidant activity was significant, with IC50 values for pure extracts of CM, white tea, and ginger being 0.071 ± 0.003, 0.073 ± 0.004, and 0.066 ± 0.004 mg/ml, respectively. For formulations M1 and M2, IC50 values were 1.030 ± 0.901 and 0.495 ± 0.496 mg/ml, respectively, showing a concentration-dependent increase in antioxidant activity. The MTT cytotoxicity assay showed high cell viability for M1 (96.1%) and M2 (133.3%) at 0.002 mg/ml, suggesting low cytotoxicity, though variability in results indicated further assay optimization. High standard deviations, 0.06 and 0.208, indicated limitations in experimental conditions emphasizing the need for improved assay parameters for accuracy. Conclusion: The mouthwash formulations, M1 and M2 Show promise, with future work focusing on increasing CM concentration and refining cytotoxicity testing methods to ensure reliable data for subsequent antibacterial and in vivo studies.
A pharmacognostic, phytochemical, and antioxidant potential of Oxalis triangularis Sharma, S.; Bhuyan, N. R.; Mohanty, J. P.
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.701

Abstract

Background: To evaluate Oxalis triangularis with pharmacognostical parameters (macroscopy, microscopy & physico-chemical analysis), phytochemical analysis, and to investigate the in-vitro antioxidant capacity of different extracts obtained. Methods: Using specific standard protocols, the following tests were performed: loss on drying, extractive value, ash value, t.s. & powder microscopy, fluorescence analysis, and phytochemical screening. The Folin-Ciocalteu technique was adopted to ascertain the amount of phenolic compounds. In-vitro antioxidant activity was evaluated using 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH)  & 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical scavenging assays. Results: The extractive values varied between solvents, ranging from 1.28% (ethyl acetate) to 18.8% (water), while the ash values were 16.25% (total), 2.9% (acid insoluble), and 10.625% (water-soluble). Numerous vascular systems, lignified trichomes, and calcium oxalate crystals were visible under a microscope. Saponins, steroids, flavonoids, phenols, anthocyanins, and alkaloids were detected by phytochemical screening; glycosides were not detected. At 200 µg/ml, the phenolic concentration of the ethanolic extract was the highest, at 1151.7 ± 59.22 µg/ml. The ethanolic extract exhibited greater DPPH (IC50 = 2.403 µg/ml) and ABTS (IC50 = 22.94 µg/ml) radical scavenging activity in comparison to the aqueous extract, i.e., (DPPH, IC50= 76.67 µg/ml & ABTS, IC50= 43.52 µg/ml). In contrast, both extracts showed notable antioxidant activity. Conclusion: A comprehensive examination of Oxalis triangularis revealed a rich reservoir of bioactive chemicals, such as phenols, which make the plant rich in antioxidant properties. This may serve as a foundation for the discovery of novel medicines.
A Piper nigrum based zinc oxide nanoparticles for anti-arthritic and antioxidant activity Dwivedi, Shradha Devi; Singh, Deependra; Singh, Manju Rawat
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.727

Abstract

Background: Zinc oxide nanoparticles (ZnONPs) are among the most effective metallic oxide nanoparticles for biological applications. They have potential anti-inflammatory and anti-oxidant properties, desirable biocompatibility, lower toxicity, and minimal cost. Methodology: Using diverse plant extracts for an ecologically friendly production of metallic nanoparticles is a better choice than conventional chemical synthesis techniques. The present study is decisive on the ZnONPs synthesis from a Piper nigrum extract (Pn-ZnONPs). Morphological characteristics of ZnONPs have been studied using UV-spectroscopy, DLS, SEM, and TEM. Further, it is analyzed for its anti-inflammatory (proteinase, collagenase, lipooxygenase, and elastase) and anti-oxidant properties (DPPH˙, SOD, NO, H2O2, and OH). Results and discussion: Synthesis of nanoparticles has been confirmed via visible spectroscopy with maximum absorbance of 350nm, having particle size and zeta potential of 80 nm and +7.4 mV, respectively. SEM and TEM analysis confirmed the nanoparticle's shape to be spherical and arranged compactly. Further, biogenic nanoparticles show desired anti-inflammatory properties by inhibiting the activity of collagenase (68.72%), elastase (65.16%), lipooxygenase (58.098%), and denaturation of protein (65.36%). It also exhibits the capability to suppress Superoxide radicals (64.87%), DPPH (65.46%), Hydrogen Peroxide (64.89%), Hydroxyl radical (68.45%), and Nitric oxide radicals (71.343%), which are responsible for the pathogenesis of many inflammatory disorders. Conclusion: This suggests that P. nigrum Zinc nanoparticles may be a promising agent in treating various inflammatory disorders, such as cancer, Rheumatoid Arthritis, Psoriasis, and others.
Development and evaluation of extended-release vildagliptin tablets using quality by design Pund, Atul K; Mundada, Atishkumar S
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.735

Abstract

Background: Extended-release dosage forms are designed to enhance patient compliance and decrease dosing frequency. However, commercially available extended-release tablets are made with synthetic or semisynthetic controlled-release polymer, which causes a ghost pill effect. The ghost pill effect is minimized by using natural polymers which are biodegradable. Aim: This study aimed to create extended-release vildagliptin tablets using natural polymer by employing the quality by Design. Method: The study involved preparing granules of vildagliptin by direct compression using co-processed polymer and other excipients and compressing them into tablets. Results & Discussion: The different micromeritic characteristics of granules were satisfactory for compressing them into tablets. The FTIR, DSC, and XRD analysis indicates no interaction between the drug and the other excipients. The drug release shows that the marketed formulation releases 97% of the drug in 8 hrs., Whereas the developed formulation extends the drug release >= 95% throughout 12hrs. Drug release kinetic study results reveal that the optimized batch obeys first-order kinetics with the Higuchi model. In vivo studies showed steady plasma levels over an extended period, achieving the objective of the current study. The stability study carried out as per the ICH guideline exhibited robustness of the formulation, with the drug content found between 96 % to 99 % at 30°C & 75 %RH and 40°C & 75 %RH. Conclusion: The extended-release formulation of vildagliptin could be successfully formulated using a combination of natural and semisynthetic polymers. This combination could prove to be effective, safe, and well tolerated, enhancing patient adherence and lowering overdose risks, thereby reducing overall diabetic treatment costs.
Design and development of thermosensitive rectal in situ gel from Luffa acutangula fruits for the treatment of ulcerative colitis Barangule, Swati P.; Maru , Avish D.
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.761

Abstract

Background: Luffa acutangula has good anti-inflammatory and antioxidant activity.  Ulcerative colitis has inflamed intestinal mucosal lining with frequent diarrhoea, mucosal, and bloody stools. The rectal administration provides high bioavailability, rapid absorption, and instant therapeutic effect. Conventional rectal formulations may be painful, while insertion and discomfort may also be experienced from the rectum leakage. Methodology: Luffa acutangula fruit extract was used for the preparation a novel rectal mucoadhesive in situ-gel by using thermosensitive polymers such as Poloxamer 407, Poloxamer 188.  HPMC K4M and carbopol 940 are two mucoadhesive polymers that are used to boost the mucoadhesive force and gel strength. The response surface method design was used to optimize the formulation. The formulated in situ gel batches were analysed by gelation temperature, gel strength, gelling ability, gelling time, viscosity and in vitro drug release and mucoadhesive strength.  Results and Discussion:  The concentration of poloxamer 407 (15%) and poloxamer 188 (3%) was optimized by design expert. The optimized formulation F10 showed 36.35±0.890 gelation temperature and 94.66±0.57 % cumulative drug release. Drug release kinetics follows Higuchi release model and according to Korsemeyer Peppa's model value of n= 1.1114 indicates supercase -II transport. Gelation temperature of mucoadhesive in situ gel (F10HP2) was found in the range 36.45±0.102°C with 91.37±0.84 % cumulative drug release. Mucoadhesive in situ gel was tested in rat model of ulcerative colitis for 7 days. Conclusion: Preclinical study of optimized formulation shows that Luffa acutangula fruit extract can stop or prevent further progression of acetic acid induced ulcerative colitis in rat model.

Page 1 of 2 | Total Record : 11

 1   2 

Filter by Year

2024 2024


Reset
Filter By Issues
All Issue Vol. 13 No. 4 (2025) Vol. 13 No. 3 (2025) Vol. 13 No. 2 (2025) Vol. 13 No. 1 (2025) Vol. 12 No. 6 (2024) Vol. 12 No. 5 (2024) Vol. 12 No. 4 (2024) Vol. 12 No. 3 (2024) Vol. 12 No. 2 (2024) Vol. 12 No. 1 (2024) Vol. 11 No. 5 (2023) Vol. 11 No. 4 (2023) Vol. 11 No. 3 (2023) Vol. 11 No. 2 (2023) Vol. 11 No. 1 (2023) Vol. 10 No. 4 (2022) Vol. 10 No. 3 (2022) Vol. 10 No. 2 (2022) Vol. 10 No. 1 (2022) Vol. 9 No. 4 (2021) Vol. 9 No. 3 (2021) Vol. 9 No. 2 (2021) Vol. 9 No. 1 (2021) Vol. 8 No. 4 (2020) Vol. 8 No. 3 (2020) Vol. 8 No. 2 (2020) Vol. 8 No. 1 (2020) Vol. 7 No. 4 (2019) Vol. 7 No. 3 (2019) Vol 7 No 3 (2019) Vol. 7 No. 2 (2019) Vol 7 No 2 (2019) Vol. 7 No. 1 (2019) Vol 7 No 1 (2019) Vol. 6 No. 4 (2018) Vol 6 No 4 (2018) Vol. 6 No. 3 (2018) Vol 6 No 3 (2018) Vol. 6 No. 2 (2018) Vol 6 No 2 (2018) Vol. 6 No. 1 (2018) Vol 6 No 1 (2018) Vol. 5 No. 4 (2017) Vol 5 No 4 (2017) Vol 5 No 3 (2017) Vol. 5 No. 3 (2017) Vol. 5 No. 2 (2017) Vol 5 No 2 (2017) Vol. 5 No. 1 (2017) Vol 5 No 1 (2017) Vol 4 No 4 (2016) Vol. 4 No. 4 (2016) Vol. 4 No. 3 (2016) Vol 4 No 3 (2016) Vol. 4 No. 2 (2016) Vol 4 No 2 (2016) Vol 4 No 1 (2016) Vol. 4 No. 1 (2016) Vol. 3 No. 4 (2015) Vol 3 No 4 (2015) Vol 3 No 3 (2015) Vol. 3 No. 3 (2015) Vol. 3 No. 2 (2015) Vol 3 No 2 (2015) Vol 3 No 1 (2015) Vol. 3 No. 1 (2015) Vol 2 No 4 (2014) Vol. 2 No. 4 (2014) Vol. 2 No. 3 (2014) Vol 2 No 3 (2014) Vol. 2 No. 2 (2014) Vol 2 No 2 (2014) Vol 2 No 1 (2014) Vol. 2 No. 1 (2014) Vol. 1 No. 1 (2013) Vol 1 No 1 (2013) More Issue